المؤلفون: Shepherd, J.H, Ballman, K, Polley, M.-Y.C, Campbell, J.D, Fan, C, Selitsky, S, Fernandez-Martinez, A, Parker, J.S, Hoadley, K.A, Hu, Z, Li, Y, Soloway, M.G, Spears, P.A, Singh, B, Tolaney, S.M, Somlo, G, Port, E.R, Ma, C, Kuzma, C, Mamounas, E, Golshan, M, Bellon, J.R, Collyar, D, Hahn, O.M, Hudis, C.A, Winer, E.P, Partridge, A, Hyslop, T, Carey, L.A, Perou, C.M, Sikov, W.M

المصدر: Journal of Clinical Oncology, 40(12)

مصطلحات موضوعية: breast tumor, Antineoplastic Combined Chemotherapy Protocols, human, phase 2 clinical trial, cyclophosphamide, minimal residual disease, Carboplatin, antineoplastic agent, cancer combination chemotherapy, bevacizumab, residual cancer burden, Breast Neoplasms, clinical outcome, cancer survival, comparative effectiveness, cancer prognosis, pathology, human cell, middle aged, controlled study, Neoplasm, Residual, randomized controlled trial, major clinical study, follow up, adult, event free survival, overall survival, Neoadjuvant Therapy, Paclitaxel

Relation: https://doi.org/10.17615/yzyb-1s66; https://cdr.lib.unc.edu/downloads/wp988x26d?file=thumbnail; https://cdr.lib.unc.edu/downloads/wp988x26d

الاتاحة: https://doi.org/10.17615/yzyb-1s66
https://cdr.lib.unc.edu/downloads/wp988x26d?file=thumbnail
https://cdr.lib.unc.edu/downloads/wp988x26d

المؤلفون: McKillip, R.P., Hahn, O.M., Sulai, N.H., Olopade, O.I., Arora, V.M., Golden, D.W.

المصدر: International Journal of Radiation Oncology*Biology*Physics ; volume 96, issue 2, page E413 ; ISSN 0360-3016

الاتاحة: http://dx.doi.org/10.1016/j.ijrobp.2016.06.1669
https://api.elsevier.com/content/article/PII:S0360301616319952?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0360301616319952?httpAccept=text/plain